MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-25-2026
Celldex Therapeutics Cash Conversion Cycle 2011-2026 | CLDX
Annual Cash Conversion Cycle Celldex Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.74 K | -6.08 K | -4.08 K | -8.3 K | -4.08 K | -1.96 K | - | - | - | - | - | - | -307 | -23.8 | -30.7 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -23.8 | -8.3 K | -3.18 K |
Quarterly Cash Conversion Cycle Celldex Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 72.1 | 116 | - | 34.1 | 76.8 | 1.55 K | - | 11.1 | 244 | 78.4 | - | 32.1 | 95.2 | 109 | - | 207 | 30.5 | 242 | 43.4 | 246 | 697 | 47.1 | 104 | 170 | 130 | 134 | 164 | 307 | 104 | 56.5 | 49.6 | 43.7 | 44.8 | 109 | 86.9 | 73.3 | 117 | 96.4 | 49.5 | 86.3 | 40.6 | 131 | 26.4 | 35.4 | 65.8 | 100 | 72 | 45.5 | 460 | 10.1 | 1.1 | 1.29 | 2 | 4.01 | 6.38 | 6.56 | 7.95 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.55 K | 1.1 | 130 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
50 | $ 4.5 | 0.45 % | $ 862 M |  Canada |
 |
Agenus
AGEN
|
-25.8 K | $ 3.64 | 9.31 % | $ 108 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
735 | $ 35.08 | -0.36 % | $ 2.03 B | USA |
 |
Akebia Therapeutics
AKBA
|
42 | $ 1.39 | 0.36 % | $ 357 M | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
46.6 | $ 331.14 | 3.85 % | $ 43.4 B | USA |
 |
Altimmune
ALT
|
7.85 K | $ 3.4 | 1.8 % | $ 300 M | USA |
 |
Amgen
AMGN
|
217 | $ 344.03 | -1.12 % | $ 185 B | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
117 | $ 12.27 | -1.68 % | $ 3.85 B | USA |
 |
Anika Therapeutics
ANIK
|
270 | $ 14.99 | 1.28 % | $ 220 M | USA |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
235 | $ 73.8 | -0.55 % | $ 1.43 B | USA |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aptorum Group Limited
APM
|
-400 | $ 0.88 | -5.16 % | $ 4.8 M | China |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.12 | -0.24 % | $ 441 M | USA |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 8.14 | 1.31 % | $ 223 M |  Israel |
 |
Ardelyx
ARDX
|
885 | $ 5.99 | 0.84 % | $ 1.44 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.06 | 1.82 % | $ 3.06 B | USA |
 |
Arvinas
ARVN
|
4.66 | $ 10.87 | 0.14 % | $ 771 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 60.28 | -1.23 % | $ 8.06 B | USA |
 |
Assembly Biosciences
ASMB
|
25.1 | $ 29.51 | 1.72 % | $ 331 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |